Imaging Neural Correlates of Ketamine Using PET/MR

The purpose of this randomized, placebo-controlled study is to investigate pharmacodynamic differences between racemic ketamine and esketamine using functional fluorodeoxyglucose ([18F]FDG) positron emission tomography/magnetic resonance imaging (PET/MR).

Topic Depression
Compound Placebo Ketamine
Country Austria
Visit trial
Status Not yet recruiting
Results Published
Start date 10 January 2020
End date 30 September 2023
Chance of happening 90%
Phase Phase I
Design Blinded
Type Interventional
Generation First
Participants 65
Sex All
Age 18- 55
Therapy No

Trial Details

The purpose of this randomized, placebo-controlled study is to investigate pharmacodynamic differences between racemic ketamine and esketamine using functional fluorodeoxyglucose ([18F]FDG) positron emission tomography/magnetic resonance imaging (PET/MR)

NCT Number NCT04587778

Sponsors & Collaborators

Medical University of Vienna
This company doesn't have a full profile yet, it is linked to a clinical trial.

Measures Used

Clinical-Administered Dissociative Symptoms Scale
The Clinical-Administered Dissociative Symptoms Scale (CADSS) is a scale used to measure dissociative states such as those induced by ketamine.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.
?>